Edward Huber has been appointed as director, analytical development and quality control at Girindus. Huber has previously worked at Marion Merrell Dow, Hoechst Marion Roussel, Aventis and Patheon.
Lonza has named Lukas Utiger as chief operating officer (COO) of the bioscience division. Utiger is currently COO of Lonza life science ingredients, replacing Anja Fiedler who has resigned for personal health reasons.
Richard Greatorex has joined Idis, a biopharm drug development consultancy, as international marketing manager. Greatorex joins Idis from CSL Behring where he was regional marketing director, Western Europe, vaccines.
Flagship Biosciences has hired Steven Potts as CEO. Dave Young will continue to serve as president. For the past three years Potts has managed Aperio.
Hermann Osterwald has been reappointed and treasurer and to the board of the International Association for Pharmaceutical Technology (APV). Osterwald is managing director, contract manufacturing services at NextPharma.
Predictive Biosciences has named James Groves as vice president (VP) of lab operations and Mark Smith as VP of information technology. Groves’ career includes time at SED Medical Laboratories. Smith has previously worked at Athena Diagnostics and Whistler.
Michael Hoye has been promoted to senior director of risk management services at Prodiance. Hoye joined Prodiance five years ago having previously worked at Jefferson Wells. Prodiance provides enterprise risk management support to a number of industries, including pharma.